Biocartis
Scientific Parc EPFL, PSE-C
Lausanne
CH-1015
Tel: 41-21-6939051
Fax: 41-21-5604291
Website: http://www.biocartis.com/
36 articles about Biocartis
-
Press release Biocartis Group NV: Biocartis Announces Nine Idylla™ Studies to be Published at Upcoming AMP 2022 Annual Meeting
10/31/2022
Biocartis Group NV announces the publication of nine performance study abstracts of its fully automated molecular diagnostics Idylla™ platform1 and assays2 at the annual meeting of the ‘Association for Molecular Pathology’, a leading molecular diagnostics conference, taking place between 1-5 November in Phoenix, Arizona.
-
Press release Biocartis Group NV: Biocartis Announces New Agreement with AstraZeneca for the Development and Marketing of a Companion Diagnostic Test for Tagrisso®
6/22/2022
Biocartis Group NV announced that it has entered into an agreement with AstraZeneca aimed at the development and applicable pre-market notification or approval with the US FDA of a novel companion diagnostic1 test on Biocartis’ molecular rapid and easy-to-use diagnostics Idylla™ platform, for use with Tagrisso®, AstraZeneca’s third-generation EGFR-TKI treatment.
-
BioSpace Global Roundup, Oct. 8
10/8/2020
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines. -
BioSpace Global Roundup, Sept. 3
9/3/2020
Biopharma and life science companies from across the globe provide updates on their pipelines and businesses. -
BioSpace Global Roundup, June 6
6/6/2019
Companies from across the globe share updates on their pipelines and growth strategies. -
Biocartis and Kite Sign Agreement for Development of Assays supporting Kite’s Therapies
6/1/2019
Biocartis Group NV, an innovative molecular diagnostics company, announced that it has entered into a Master Development and Commercialization Agreement with Kite, a Gilead Company.
-
Companies across Europe and Asia provide information about deal, clinical trials and more, with news from Synaptive Medical, Epic, Inventiva, Velabs, and more.
-
Genomic Health and Biocartis Expand Collaboration to Urology with the Development of an Idylla™ Oncotype DX® Genomic Prostate Score® Test
12/3/2018
Genomic Health, Inc. and Biocartis Group NV today announced they have expanded their exclusive collaboration into the field of urology with the development of an in vitro diagnostic (IVD) version of the Oncotype DX® Genomic Prostate Score® (GPS™) test on Biocartis' Idylla™ platform and potentially additional cancer tests that can be performed locally by laboratory partners and in hospitals around the world.
-
Horizon Discovery partners with Biocartis to provide reference standards for recently launched Idylla™ microsatellite instability assay
11/1/2018
First commercially available reference standard for microsatellite instability (MSI) testing
-
Cellectis announced it had appointed Stefan Scherer to the role of senior vice president Clinical Development and deputy chief medical officer.
-
Biocartis Group NV: Disclosure of a Transparency Notification - Jan. 12, 2018
1/12/2018
The Notification contains the following information:
-
The firm said it sold the shares at an issue price of €12.50 each, and that the total 6.4 million shares represent approximately 14.3 percent of its outstanding shares.
-
Genomic Health And Biocartis Announce Agreement To Develop An Idylla IVD Oncotype DX Breast Cancer Test To Broaden Global Patient Access
9/13/2017
-
Biocartis' Idylla Instrument And Idylla Console Exempt From U.S. FDA 510(K) Notification Requirements
7/12/2017
-
Biocartis And A*STAR’s ETPL Initiate Development Of Breast Cancer Assay To Guide Therapy Selection
7/10/2017
-
Biocartis Announces Launch Of Influenza-Respiratory Virus Panel On The Idylla Platform
12/1/2015
-
Biocartis Q3 2015 Business Update
11/20/2015
-
Biocartis Announces H1 2015 Results And Strengthening Of Management Team
9/14/2015
-
Biocartis Release: Notice Of Results For The Six Months Ended 30 June 2015
9/3/2015
-
Biocartis And Fast-Track Diagnostics Sign Strategic Collaboration In Infectious Diseases
5/27/2015